Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.

"Declarations Conflict of interestDr. Ohashi has received honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., and Novartis Pharma K.K; grants from Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., Amgen K.K., and Novartis Pharma K.K; and receipt of research reagents from Genentech, Inc. and Novartis Pharma K.K. outside the submitted work. Dr. Ninomiya has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., MSD K.K., Ono Pharmaceutical CO., LTD., Takeda Pharmaceutical CO., LTD., Pfizer Japan Inc., Bristol Myers Squibb K.K., Elekta K.K., Janssen Pharmaceutical K.K., and Daiichi Sankyo Co. Ltd. outside the submitted work. Dr. Tsubata has received honoraria from Daiichi Sankyo Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD., and Bristol Myers Squibb K.K.; and subsidies or donations from Pfizer Health Research Foundation outside the submitted work. Dr. Ishikawa has received honoraria from AstraZeneca K.K. and Nippon Boehringer-Ingelheim Co., Ltd. outside the submitted work. Dr. Kodani has received AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical CO., LTD., Pfizer Japan Inc., TAIHO PHARMACEUTICAL CO., LTD., and Takeda Pharmaceutical CO., LTD. outside the submitted work. Dr. Kuyama has received honoraria from Chugai Pharmaceutical Co. Ltd., Bristol Myers Squibb K.K., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Pfizer Japan Inc., Eli Lilly Japan K.K., MSD K.K., TAIHO PHARMACEUTICAL CO., LTD., Sanofi K.K., Kyowa Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and Novartis Pharma K.K. outside the submitted work. Dr. Takigawa has received grants and personal fees from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., TAIHO PHARMACEUTICAL CO., LTD., Nippon Boehringer-Ingelheim Co., Ltd., and; grants from Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; and personal fees from AstraZeneca K.K., Pfizer Japan Inc., Merck Japan, MSD K.K., Ono Pharmaceutical Co. Ltd. and Bristol Myers Squibb K.K. outside the submitted work. Dr. Fujimoto received honoraria from Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., and Nippon Kayaku Co., Ltd. outside the submitted work. Dr. Fujiwara has received honoraria from MSD K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Sanofi K.K., and Eli Lilly Japan K.K. outside the submitted work. Dr. Kiura has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Merk Biopharma, TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Japan Inc. Bristol Myers Squibb K.K., NipponKayaku Co., Ltd., Ono Pharmaceutical Co. Ltd., and MSD K.K.; research fund from Nippon Boehringer-Ingelheim Co., Ltd., Ono Pharmaceutical Co. Ltd., Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Teijin pharma Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi Pharma Co., Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Chugai Pharmaceutical; and consulting fees from Nippon Kayaku Co., Ltd., and Nipro Corp. outside the submitted work. Dr. Hotta has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical CO., LTD., MSD K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer-Ingelheim Co., Ltd., and NipponKayaku Co., Ltd.; and research fund from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., and Abbvie Inc. outside the submitted work. Conflict of interest Dr. Ohashi has received honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., and Novartis Pharma K.K; grants from Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., Amgen K.K., and Novartis Pharma K.K; and receipt of research reagents from Genentech, Inc. and Novartis Pharma K.K. outside the submitted work. Dr. Ninomiya has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., MSD K.K., Ono Pharmaceutical CO., LTD., Takeda Pharmaceutical CO., LTD., Pfizer Japan Inc., Bristol Myers Squibb K.K., Elekta K.K., Janssen Pharmaceutical K.K., and Daiichi Sankyo Co. Ltd. outside the submitted work. Dr. Tsubata has received honoraria from Daiichi Sankyo Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD., and Bristol Myers Squibb K.K.; and subsidies or donations from Pfizer Health Research Foundation outside the submitted work. Dr. Ishikawa has received honoraria from AstraZeneca K.K. and Nippon Boehringer-Ingelheim Co., Ltd. outside the submitted work. Dr. Kodani has received AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical CO., LTD., Pfizer Japan Inc., TAIHO PHARMACEUTICAL CO., LTD., and Takeda Pharmaceutical CO., LTD. outside the submitted work. Dr. Kuyama has received honoraria from Chugai Pharmaceutical Co. Ltd., Bristol Myers Squibb K.K., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Pfizer Japan Inc., Eli Lilly Japan K.K., MSD K.K., TAIHO PHARMACEUTICAL CO., LTD., Sanofi K.K., Kyowa Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and Novartis Pharma K.K. outside the submitted work. Dr. Takigawa has received grants and personal fees from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., TAIHO PHARMACEUTICAL CO., LTD., Nippon Boehringer-Ingelheim Co., Ltd., and; grants from Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; and personal fees from AstraZeneca K.K., Pfizer Japan Inc., Merck Japan, MSD K.K., Ono Pharmaceutical Co. Ltd. and Bristol Myers Squibb K.K. outside the submitted work. Dr. Fujimoto received honoraria from Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., and Nippon Kayaku Co., Ltd. outside the submitted work. Dr. Fujiwara has received honoraria from MSD K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Sanofi K.K., and Eli Lilly Japan K.K. outside the submitted work. Dr. Kiura has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Merk Biopharma, TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Japan Inc. Bristol Myers Squibb K.K., NipponKayaku Co., Ltd., Ono Pharmaceutical Co. Ltd., and MSD K.K.; research fund from Nippon Boehringer-Ingelheim Co., Ltd., Ono Pharmaceutical Co. Ltd., Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Teijin pharma Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi Pharma Co., Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Chugai Pharmaceutical; and consulting fees from Nippon Kayaku Co., Ltd., and Nipro Corp. outside the submitted work. Dr. Hotta has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical CO., LTD., MSD K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer-Ingelheim Co., Ltd., and NipponKayaku Co., Ltd.; and research fund from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., and Abbvie Inc. outside the submitted work."

"Funding Open Access funding provided by Okayama University. This research received a research grant in 2016 for medicine from Chugoku Occupational Health Association (non-profit organization)."

"This observational study was registered at the prospective umbrella-type lung cancer registry (CS-Lung-003; UMIN000026696) (Nishii et al. 2021; Kudo et al. 2022) and included patients with lung cancer enrolled from 31 collaborating hospitals between July 2017 and September 2020. This study aimed to investigate clinical practice patterns and treatment efficacy in patients with EGFR-mutant lung cancer. Data for this study were collected in August 2021. This study was approved by the ethics committee of the participating hospital (no. 1703–055; Institutional Review Board of Okayama University Hospital) and all patients provided written informed consent."